Once-daily versus twice-daily ramipril for kidney health in CKD patients with reduced ejection fraction heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, parallel-assignment trial compares ramipril 10 mg once daily with ramipril 5 mg twice daily in adults with CKD stage 3–5 (not on dialysis) and heart failure with reduced ejection fraction (EF < 40%). Participants receive assigned dosing for 30 days while researchers measure plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C to track renal and inflammatory responses. The trial excludes patients on dialysis, those taking ARBs or sacubitril-valsartan, and patients with ACE inhibitor intolerance or angioedema history. The single-site study is conducted at UNS Hospital in Kartasura, Central Java.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female or Male with age \>18 years old
* Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \< 40%)

Exclusion Criteria:

* Receiving hemodialysis therapy
* History of intolerance to ACE inhibitors
* Refractory hyperkalemia
* Pregnancy
* History of angioedema to ACE inhibitors
* Receiving sacubitril-valsartan therapy
* Receiving ARB therapy
* Hypotension with blood pressure \<90/60, or patients in shock.

Where it's running

• UNS Hospital
  Kartasura, Central Java, Indonesia Recruiting

Study contacts

• Study coordinator: Evi L Wulandari, MD., Internist
• Email: evililiek@staff.uns.ac.id
• Phone: (+62)821-3587-2749

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Atrial Shunt to Help Heart Failure With Reduced Ejection Fraction

  This study tests whether an atrial shunt implanted after heart catheterization helps people with HFrEF when added to standard heart failure therapy.

  Recruiting Phase 2/3 Beijing Anzhen Hospital · Beijing, Beijing Municipality · NCT07820410

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.